Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1999 1
2003 2
2006 1
2009 2
2010 3
2012 1
2014 2
2015 2
2016 2
2017 1
2018 1
2019 2
2020 3
2021 7
2022 9
2023 9
2024 11
2025 12
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean M. shafi (1 results)?
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Issa GC, et al. J Clin Oncol. 2025 Jan;43(1):75-84. doi: 10.1200/JCO.24.00826. Epub 2024 Aug 9. J Clin Oncol. 2025. PMID: 39121437 Free PMC article. Clinical Trial.
Revumenib was administered once every 12 hours, at 163 mg (95 mg/m(2) if weight <40 kg) with a strong cytochrome P450 inhibitor, in 28-day cycles. The primary end points were the rate of complete remission (CR) or CR with partial hematologic recovery (CR + CRh) and safe …
Revumenib was administered once every 12 hours, at 163 mg (95 mg/m(2) if weight <40 kg) with a strong cytochrome P450 inhibitor, i …
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, Žučenka A, de Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, Kühn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, Döhner H, Greco C, Kovacsovics T, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly JS. Arellano ML, et al. Blood. 2025 Aug 28;146(9):1065-1077. doi: 10.1182/blood.2025028357. Blood. 2025. PMID: 40332046 Free PMC article. Clinical Trial.
Diagnostic Endoscopic Ultrasound.
Radlinski MJ, Zaver HB, Shami VM. Radlinski MJ, et al. Gastroenterol Clin North Am. 2024 Dec;53(4):663-681. doi: 10.1016/j.gtc.2024.08.015. Epub 2024 Oct 5. Gastroenterol Clin North Am. 2024. PMID: 39489581 Review.
Evolution of interventional endoscopic ultrasound.
Radlinski MJ, Strand DS, Shami VM. Radlinski MJ, et al. Gastroenterol Rep (Oxf). 2023 Jun 30;11:goad038. doi: 10.1093/gastro/goad038. eCollection 2023. Gastroenterol Rep (Oxf). 2023. PMID: 37398926 Free PMC article. Review.
Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
GBD 2023 Diarrhoeal Disease and Enteric Infectious Diseases Collaborators. GBD 2023 Diarrhoeal Disease and Enteric Infectious Diseases Collaborators. Lancet Infect Dis. 2026 Jun 2:S1473-3099(26)00194-5. doi: 10.1016/S1473-3099(26)00194-5. Online ahead of print. Lancet Infect Dis. 2026. PMID: 42229499
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Malkin E, Bethony JM, Walsh EE, Graciaa DS, Samaha H, Sherman AC, Walsh SR, Abate G, Oikonomopoulou Z, El Sahly HM, Martin TCS, Kamidani S, Smith MJ, Ladner BG, Porterfield L, Dunstan M, Wald A, Davis T, Atmar RL, Mulligan MJ, Lyke KE, Posavad CM, Meagher MA, Stephens DS, Neuzil KM, Abebe K, Hill H, Albert J, Telu K, Mu J, Lewis TC, Giebeig LA, Eaton A, Netzl A, Wilks SH, Türeli S, Makhene M, Crandon S, Montefiori DC, Makowski M, Smith DJ, Nayak SU, Roberts PC, Beigel JH; COVAIL Study Group. Branche AR, et al. Nat Med. 2023 Sep;29(9):2334-2346. doi: 10.1038/s41591-023-02503-4. Epub 2023 Aug 28. Nat Med. 2023. PMID: 37640860 Free PMC article. Clinical Trial.
Individual genomic loci, transcript level, and biochemical profile of immune and antioxidant markers associated with genetically identified bacterial mastitis in Shami goats in Egypt.
Ebissy E, Darwish A, Hafez AA, Ateya A, El-Sayed A. Ebissy E, et al. Open Vet J. 2024 Jan;14(1):370-388. doi: 10.5455/OVJ.2024.v14.i1.34. Epub 2024 Jan 31. Open Vet J. 2024. PMID: 38633191 Free PMC article.
AIM: The study aimed to compare culture methods and multiplex PCR (m-PCR) in the detection of the most three common mastitis-causing pathogens (Staphylococcus aureus, Escherichia coli, and Streptococcus spp.) and investigate the gene expression, single nucleotide polymorph …
AIM: The study aimed to compare culture methods and multiplex PCR (m-PCR) in the detection of the most three common mastitis-causing …
74 results